Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.
Human immunodeficiency virus (HIV) type 1 DNA assay data were obtained at baseline from 111 HIV-1-positive subjects who were treated with nucleosides. Higher baseline DNA level, HIV-1 RNA level, and infectious titer were comparably associated with an increased hazard of disease progression (each P<.03). Only DNA level was significantly associated with survival (adjusted hazard ratio for 1 log(10) higher level, 3.99; 95% confidence interval, 1.44-11.09; P=.008).
Tierney
Camlin
C
Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts 02115, USA. tierney@sdac.harvard.edu
Lathey
Janet L
JL
Christopherson
Cindy
C
Bettendorf
Daniel M
DM
D'Aquila
Richard T
RT
Hammer
Scott M
SM
Katzenstein
David A
DA
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000401:mortality / Q000821:virology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004279:DNA, Viral / Q000032:analysis*; D016049:Didanosine / Q000008:administration & dosage; D018450:Disease Progression; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D015999:Multivariate Analysis; D011379:Prognosis; D012367:RNA, Viral / Q000097:blood; D016047:Zalcitabine / Q000008:administration & dosage; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D004279:DNA, Viral; D012367:RNA, Viral; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine